• Antibody response of hepatitis A [ Time Frame: 4 weeks post dose 2 ] [ Designated as safety issue: No ]
• Antibody response to Hib and antibody titers for pertussis [ Time Frame: 4 weeks post vaccination ] [ Designated as safety issue: No ]
• Safety profile of Hepatitis A Vaccine, Inactivated with other vaccines. Safety profile of Hepatitis A Vaccine, Inactivated after any dose [ Time Frame: 14 days following vaccination ] [ Designated as safety issue: Yes ]

Stage 1: Hepatitis A vaccine will be given either alone or together with Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine or Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) at the first dose. A second dose of hepatitis A vaccine will be given 6 months later. Responses to the vaccines and safety data will be collected after each dose. Stage 2: Two (2) doses Hepatitis A vaccine will be administered at least 6 months apart. Safety data will be collected after each dose.

• Biological: Comparator: Vaqta
• Biological: Comparator: Infanrix
• Biological: Comparator: PedvaxHIB

• Experimental: VAQTA 0.5 ml injection, Infanrix 0.5 ml injection, PedvaxHIB 0.5 ml injection, VAQTA 0.5 ml injection
• Experimental: Infanrix 0.5 ml injection, PedvaxHIB 0.5 ml injection, VAQTA 0.5 ml injection, VAQTA 0.5 ml injection
• Experimental: VAQTA 0.5 ml injection, PedvaxHIB 0.5 ml injection, VAQTA 0.5 ml injection
• Experimental: PedvaxHIB 0.5 ml injection, VAQTA 0.5 ml injection, VAQTA 0.5 ml injection
• Experimental: VAQTA 0.5 ml injection, VAQTA 0.5 ml injection

Inclusion Criteria:

• Stage 1) Healthy males and females 15 months of age with no active liver disease and a negative history of hepatitis A who have been vaccinated against Haemophilus influenzae type b (Hib), diphtheria, tetanus, and pertussis diseases
• Stage 2) Healthy males and females 12 to 17 months of age with no active liver disease and a negative history of hepatitis A

Exclusion Criteria:

• Stage 1) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, a history of seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine, or a bleeding disorder
• Stage 2) Males and females previously vaccinated with hepatitis A vaccine, any immune deficiency, a history of allergy to any of the vaccine components, or a history of bleeding disorder